- Topic
2k Popularity
4k Popularity
33k Popularity
3k Popularity
496 Popularity
111k Popularity
26k Popularity
26k Popularity
7k Popularity
14k Popularity
- Pin
- 📢 Gate has released its latest Proof of Reserves report!
As of July 11, 2025:
💰 Total reserves reached $10.504 billion
📈 Reserve ratio stands at 126.03%
✅ Covers over 350 types of user assets
🔼 Surplus reserves increased 10.66% to $2.17 billion
Committed to transparency and user fund security.
📎 Learn more: https://www.gate.com/proof-of-reserves
- 📢 Gate Square #Creator Campaign Phase 1# is now live – support the launch of the PUMP token sale!
The viral Solana-based project Pump.Fun ($PUMP) is now live on Gate for public sale!
Join the Gate Square Creator Campaign, unleash your content power, and earn rewards!
📅 Campaign Period: July 11, 18:00 – July 15, 22:00 (UTC+8)
🎁 Total Prize Pool: $500 token rewards
✅ Event 1: Create & Post – Win Content Rewards
📅 Timeframe: July 12, 22:00 – July 15, 22:00 (UTC+8)
📌 How to Join:
Post original content about the PUMP project on Gate Square:
Minimum 100 words
Include hashtags: #Creator Campaign
- 🎉 [Gate 30 Million Milestone] Share Your Gate Moment & Win Exclusive Gifts!
Gate has surpassed 30M users worldwide — not just a number, but a journey we've built together.
Remember the thrill of opening your first account, or the Gate merch that’s been part of your daily life?
📸 Join the #MyGateMoment# campaign!
Share your story on Gate Square, and embrace the next 30 million together!
✅ How to Participate:
1️⃣ Post a photo or video with Gate elements
2️⃣ Add #MyGateMoment# and share your story, wishes, or thoughts
3️⃣ Share your post on Twitter (X) — top 10 views will get extra rewards!
👉
Innovent Biologics: Positive Results from Phase II Clinical Trial of Innovative Drug ICP-488
Jinshi data news on October 9th, Norcheng Jianhua announced in the evening that the company's innovative drug ICP-488 achieved positive clinical trial results in a phase II randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis. The results showed that patients treated with 6mg and 9mg (once daily) of ICP-488 had significant improvement in PASI75 at week 12 compared to patients receiving placebo. In addition, the proportion of patients receiving ICP-488 treatment who achieved PASI90, PASI100, and static Physician Global Assessment (sPGA) 0/1 (i.e., complete or near-complete clearance of skin lesions) was significantly higher than that in the placebo group.